Long-term pharmacotherapy of obsessive-compulsive disorder: A double-blind controlled study

Emanuela Mundo, Silvio Riccardo Bareggi, Rodolfo Pirola, Laura Bellodi, Enrico Smeraldi

Research output: Contribution to journalArticle

Abstract

The aim of this study was to investigate whether obsessive-compulsive patients previously treated successfully with clomipramine or fluvoxamine could tolerate reduction of the daily dosage without worsening of the clinical condition. Thirty informed obsessive-compulsive patients, given a diagnosis according to DSM-III-R criteria, were recruited consecutively into the study. Patients were blindly assigned to one of the groups of treatment with different rates of reduction of the previously effective daily drug dosage: group 1 (control group, no reduction), group 2 (reduction of 33-40%), and group 3 (reduction of 60-66%). The entire study lasted 102 days. From baseline to the end of the study, the clinical condition was evaluated by the administration of standardized tests (Yale-Brown Obsessive-Compulsive Scale, Hamilton Rating Scale for Depression, Clinical Global Impression [CGI] scale), and blood samples were collected for plasma drug level determinations. The criterion for discontinuation of the study was the worsening of obsessive-compulsive symptoms, arbitrarily defined by an increase of > 5% from the baseline total Yale-Brown Obsessive-Compulsive Scale score, as measured in two successive assessments, and a worsening of global clinical condition as measured by the CGI scale. The main result of the study was borne out from the survival analysis. There were no significant differences in the cumulative proportion of patients from each group of treatment who did not worsen during the 102 days of observation. This preliminary result, which needs to be confirmed in larger samples, suggests that long-term maintenance therapy for obsessive-compulsive disorder might be provided with lower dosages of the antiobsessional drug, with clear advantages for tolerability and compliance.

Original languageEnglish
Pages (from-to)4-10
Number of pages7
JournalJournal of Clinical Psychopharmacology
Volume17
Issue number1
DOIs
Publication statusPublished - Feb 1997

Fingerprint

Obsessive-Compulsive Disorder
Double-Blind Method
Drug Therapy
Pharmaceutical Preparations
Fluvoxamine
Clomipramine
Survival Analysis
Diagnostic and Statistical Manual of Mental Disorders
Compliance
Therapeutics
Observation
Depression
Control Groups

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Long-term pharmacotherapy of obsessive-compulsive disorder : A double-blind controlled study. / Mundo, Emanuela; Bareggi, Silvio Riccardo; Pirola, Rodolfo; Bellodi, Laura; Smeraldi, Enrico.

In: Journal of Clinical Psychopharmacology, Vol. 17, No. 1, 02.1997, p. 4-10.

Research output: Contribution to journalArticle

Mundo, Emanuela ; Bareggi, Silvio Riccardo ; Pirola, Rodolfo ; Bellodi, Laura ; Smeraldi, Enrico. / Long-term pharmacotherapy of obsessive-compulsive disorder : A double-blind controlled study. In: Journal of Clinical Psychopharmacology. 1997 ; Vol. 17, No. 1. pp. 4-10.
@article{750d4377257f458787b0a09a1348ced1,
title = "Long-term pharmacotherapy of obsessive-compulsive disorder: A double-blind controlled study",
abstract = "The aim of this study was to investigate whether obsessive-compulsive patients previously treated successfully with clomipramine or fluvoxamine could tolerate reduction of the daily dosage without worsening of the clinical condition. Thirty informed obsessive-compulsive patients, given a diagnosis according to DSM-III-R criteria, were recruited consecutively into the study. Patients were blindly assigned to one of the groups of treatment with different rates of reduction of the previously effective daily drug dosage: group 1 (control group, no reduction), group 2 (reduction of 33-40{\%}), and group 3 (reduction of 60-66{\%}). The entire study lasted 102 days. From baseline to the end of the study, the clinical condition was evaluated by the administration of standardized tests (Yale-Brown Obsessive-Compulsive Scale, Hamilton Rating Scale for Depression, Clinical Global Impression [CGI] scale), and blood samples were collected for plasma drug level determinations. The criterion for discontinuation of the study was the worsening of obsessive-compulsive symptoms, arbitrarily defined by an increase of > 5{\%} from the baseline total Yale-Brown Obsessive-Compulsive Scale score, as measured in two successive assessments, and a worsening of global clinical condition as measured by the CGI scale. The main result of the study was borne out from the survival analysis. There were no significant differences in the cumulative proportion of patients from each group of treatment who did not worsen during the 102 days of observation. This preliminary result, which needs to be confirmed in larger samples, suggests that long-term maintenance therapy for obsessive-compulsive disorder might be provided with lower dosages of the antiobsessional drug, with clear advantages for tolerability and compliance.",
author = "Emanuela Mundo and Bareggi, {Silvio Riccardo} and Rodolfo Pirola and Laura Bellodi and Enrico Smeraldi",
year = "1997",
month = "2",
doi = "10.1097/00004714-199702000-00002",
language = "English",
volume = "17",
pages = "4--10",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Long-term pharmacotherapy of obsessive-compulsive disorder

T2 - A double-blind controlled study

AU - Mundo, Emanuela

AU - Bareggi, Silvio Riccardo

AU - Pirola, Rodolfo

AU - Bellodi, Laura

AU - Smeraldi, Enrico

PY - 1997/2

Y1 - 1997/2

N2 - The aim of this study was to investigate whether obsessive-compulsive patients previously treated successfully with clomipramine or fluvoxamine could tolerate reduction of the daily dosage without worsening of the clinical condition. Thirty informed obsessive-compulsive patients, given a diagnosis according to DSM-III-R criteria, were recruited consecutively into the study. Patients were blindly assigned to one of the groups of treatment with different rates of reduction of the previously effective daily drug dosage: group 1 (control group, no reduction), group 2 (reduction of 33-40%), and group 3 (reduction of 60-66%). The entire study lasted 102 days. From baseline to the end of the study, the clinical condition was evaluated by the administration of standardized tests (Yale-Brown Obsessive-Compulsive Scale, Hamilton Rating Scale for Depression, Clinical Global Impression [CGI] scale), and blood samples were collected for plasma drug level determinations. The criterion for discontinuation of the study was the worsening of obsessive-compulsive symptoms, arbitrarily defined by an increase of > 5% from the baseline total Yale-Brown Obsessive-Compulsive Scale score, as measured in two successive assessments, and a worsening of global clinical condition as measured by the CGI scale. The main result of the study was borne out from the survival analysis. There were no significant differences in the cumulative proportion of patients from each group of treatment who did not worsen during the 102 days of observation. This preliminary result, which needs to be confirmed in larger samples, suggests that long-term maintenance therapy for obsessive-compulsive disorder might be provided with lower dosages of the antiobsessional drug, with clear advantages for tolerability and compliance.

AB - The aim of this study was to investigate whether obsessive-compulsive patients previously treated successfully with clomipramine or fluvoxamine could tolerate reduction of the daily dosage without worsening of the clinical condition. Thirty informed obsessive-compulsive patients, given a diagnosis according to DSM-III-R criteria, were recruited consecutively into the study. Patients were blindly assigned to one of the groups of treatment with different rates of reduction of the previously effective daily drug dosage: group 1 (control group, no reduction), group 2 (reduction of 33-40%), and group 3 (reduction of 60-66%). The entire study lasted 102 days. From baseline to the end of the study, the clinical condition was evaluated by the administration of standardized tests (Yale-Brown Obsessive-Compulsive Scale, Hamilton Rating Scale for Depression, Clinical Global Impression [CGI] scale), and blood samples were collected for plasma drug level determinations. The criterion for discontinuation of the study was the worsening of obsessive-compulsive symptoms, arbitrarily defined by an increase of > 5% from the baseline total Yale-Brown Obsessive-Compulsive Scale score, as measured in two successive assessments, and a worsening of global clinical condition as measured by the CGI scale. The main result of the study was borne out from the survival analysis. There were no significant differences in the cumulative proportion of patients from each group of treatment who did not worsen during the 102 days of observation. This preliminary result, which needs to be confirmed in larger samples, suggests that long-term maintenance therapy for obsessive-compulsive disorder might be provided with lower dosages of the antiobsessional drug, with clear advantages for tolerability and compliance.

UR - http://www.scopus.com/inward/record.url?scp=0031014507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031014507&partnerID=8YFLogxK

U2 - 10.1097/00004714-199702000-00002

DO - 10.1097/00004714-199702000-00002

M3 - Article

C2 - 9004050

AN - SCOPUS:0031014507

VL - 17

SP - 4

EP - 10

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 1

ER -